CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 1 enrolled
Drug / intervention
Pioglitazonedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01655719
NCT01655719Phase 2Completed
CompareCT.gov

Phase 2 Study of Pioglitazone in Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene

University of Michigan·interventional·Posted Aug 2, 2012·Updated Oct 26, 2017

In Brief

A Phase 2 clinical trial evaluating Pioglitazone for Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene. Completed, enrolled 1 participant across 4 sites.

Detailed Summary

Through this trial the investigators hope to learn if a drug, Actos (pioglitazone), is useful in treating a certain kind of metastatic thyroid cancer. Actos is approved by the FDA to treat diabetes. It has not been approved by the FDA to treat cancer, so its use in this study is considered experimental.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedAug 2, 2012
Enrollment StartApr 1, 2012
Primary CompletionMar 31, 2017
TodayJul 2, 2026
Enrollment to primary: 5 yearsPosted 13.9 years ago

Interventions

Pioglitazonedrug